Infantile Spasms Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Infantile Spasms Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Infantile Spasms Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Infantile Spasms, historical and forecasted epidemiology as well as the Infantile Spasms market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Infantile Spasms Market by downloading the comprehensive report from DelveInsight @ Infantile Spasms Treatment Market Size
Key Takeaways from the Infantile Spasms Market Report
- In August 2024:- Jazz Pharmaceuticals- An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Participants With Tuberous Sclerosis Complex (Age 1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) Who Experience Inadequately-controlled Seizures
- The overall prevalence of infantile spasms was found to be about 1 in 10,000 children by the age of 10 years.
- The total diagnosed prevalent cases of Infantile Spasms are expected to rise between 2024 and 2034, driven by growing awareness and advancements in genetic testing and diagnostic technologies. These developments are anticipated to improve detection rates and overall case identification, reflecting a more informed and proactive healthcare approach.
- The number of birth prevalent cases of infantile spasms is projected to rise during the forecast period from 2024 to 2034. This increase is attributed to several factors, including a growing prevalence of underlying neurological conditions such as brain injuries, metabolic disorders, and genetic abnormalities, which are recognized risk factors for infantile spasms.
- The leading Infantile Spasms Companies such as H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, and others.
- Promising Infantile Spasms Therapies such as GWP42003-P, and others.
Gain a competitive edge in the Infantile Spasms Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Infantile Spasms Treatment Drugs
Infantile Spasms Epidemiology Segmentation in the 7MM
- Infantile Spasms Birth Prevalent Cases
- Total Infantile Spasms Diagnosed Prevalent Cases
- Infantile Spasms Gender-specific Diagnosed Prevalent Cases
- Infantile Spasms Type-specific Diagnosed Prevalent Cases
- Infantile Spasms Treated Cases
Infantile Spasms Market Insights
Infantile spasms, also known as West syndrome, require immediate and effective treatment to prevent long-term neurological damage. The American Academy of Neurology and the Child Neurology Society recommend two primary treatments: hormonal therapy and vigabatrin. Hormonal therapy typically involves the use of adrenocorticotropic hormone (ACTH) or prednisolone. While there is some debate about which is more effective, ACTH is often preferred. The treatment involves a high initial dose for at least two weeks, followed by a gradual tapering over several weeks or months. ACTH is administered as an injection, with initial doses given in the hospital to monitor any side effects. Parents are then instructed on how to give the injections at home for a course that typically lasts around six weeks. Hormonal therapy has a success rate of 40% to 80% in resolving spasms, but about one-third of children may experience a relapse after initially responding to the treatment.
Discover key developments and opportunities in the Infantile Spasms Market. Click here to learn more from DelveInsight’s latest report @ Infantile Spasms Market Size
Infantile Spasms Market Insights
Vigabatrin, the other first-line treatment, is particularly effective in children with tuberous sclerosis complex (TSC). In this subgroup, it often leads to better outcomes. However, for children without TSC, the response rates to vigabatrin are more modest, ranging between 30% and 40%. Similar to hormonal therapy, approximately one-third of children who respond to vigabatrin treatment may relapse. In cases where the first-line treatments are not effective or suitable, other therapeutic options may be considered. These include dietary interventions such as the ketogenic diet, or alternative anti-seizure medications like pyridoxine, topiramate, zonisamide, and felbamate. Cannabidiol has also been explored as a treatment option. In some cases, surgical interventions such as brain resection, corpus callosotomy, or vagus nerve stimulation may be necessary. While these treatments are available, they are generally less established and have lower success rates compared to hormonal therapy and vigabatrin.
Infantile Spasms Treatment Market
The treatment landscape for infantile spasms is marked by significant unmet needs that impede optimal patient care. A primary challenge is delayed diagnosis, as the subtle nature of the spasms can result in late intervention, which adversely impacts developmental outcomes; timely treatment is essential for enhancing prognosis. Furthermore, the lack of robust clinical data leads to variability in treatment protocols among healthcare providers, creating uncertainty about the most effective first-line therapies. Existing medications, such as ACTH and vigabatrin, carry potential side effects and are not universally effective, resulting in a high relapse rate post-treatment. Addressing these issues is critical to improving care and outcomes for children affected by infantile spasms.
Infantile Spasms Emerging Drugs Profile
- CER-0001 (tricaprilin): Cerecin
CER-0001 (tricaprilin) is an investigational drug developed by Cerecin for various neurological indications, including infantile spasms. As a ketogenic compound, CER-0001 aims to harness the multiple activities and benefits of ketone bodies. Cerecin’s infantile spasms program has received several designations, including rare pediatric disease designation and orphan drug designation, along with clearance from the US FDA to study CER-0001 under an Investigational New Drug (IND) application. The European Medicines Agency (EMA) has also granted orphan drug designation.
- ANAVEX 2-73: Anavex Life Sciences
ANAVEX 2-73 is an orally available drug candidate designed to target sigma-1 and muscarinic receptors. It has received orphan drug designation for the treatment of infantile spasms. This compound, known as blarcamesine, has been utilized in various preclinical studies, including infantile spasms. In animal models, ANAVEX 2-73 has shown a significant reduction in the frequency of spasms in infant rats with epileptic spasms.
Download DelveInsight’s Infantile Spasms Market report today and stay ahead in this rapidly evolving field. @ Infantile Spasms Clinical Trials
Scope of the Infantile Spasms Market Report
- Coverage- 7MM
- Infantile Spasms Companies- H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, and others.
- Infantile Spasms Therapies- GWP42003-P, and others.
- Infantile Spasms Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Infantile Spasms Unmet Needs, KOL’s views, Analyst’s views, Infantile Spasms Market Access and Reimbursement
Download the report to understand which factors are driving Infantile Spasms Market Trends @ Infantile Spasms Market Trends
Table of Content
1. Key Insights
2. Executive Summary of Infantile Spasm
3. Competitive Intelligence Analysis for Infantile Spasm
4. Infantile Spasm: Market Overview at a Glance
5. Infantile Spasm: Disease Background and Overview
6. Patient Journey
7. Infantile Spasm Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Infantile Spasm Unmet Needs
10. Key Endpoints of Infantile Spasm Treatment
11. Infantile Spasm Marketed Products
12. Infantile Spasm Emerging Therapies
13. Infantile Spasm: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Infantile Spasm
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Infantile Spasms Treatment Market Size in the 7MM is expected to increase by 2034, estimates DelveInsight